^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC Patients Receiving Leronlimab Suggests an Increase of 3600% in 12-month OS in 75% of Patients with a Lower Level of Circulating Cells After Leronlimab Induction or at Baseline; 12-month PFS Continues at Near 600% Increase

Published date:
11/03/2021
Excerpt:
CytoDyn Inc…announced today updated results from its current cancer study using leronlimab (in varying doses) to treat 28 patients with CCR5+ Metastatic Triple-Negative Breast Cancer...75% of the patients who exhibited a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival (“OS”) (p = 0.0004), as compared to a 980% increase in OS...The updated analysis also suggested a 580% increase in 12-month Progression Free Survival (“PFS”) (p = 0.0354), as compared to up to a 660% increase in PFS...